MVCD6
MCID: MCR130
MIFTS: 40

Microvascular Complications of Diabetes 6 (MVCD6)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Microvascular Complications of Diabetes 6

MalaCards integrated aliases for Microvascular Complications of Diabetes 6:

Name: Microvascular Complications of Diabetes 6 57 73 12 38
Microvascular Complications of Diabetes, Susceptibility to, 6 57 28 5
Diabetic Nephropathy 73 71
Mvcd6 57 73
Nephropathy, Diabetic, Susceptibility to 57
Nephropathy, Diabetic 57

Classifications:



External Ids:

OMIM® 57 612634
OMIM Phenotypic Series 57 PS603933
MeSH 43 D048909
UMLS 71 C0011881

Summaries for Microvascular Complications of Diabetes 6

UniProtKB/Swiss-Prot: 73 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 6, also known as microvascular complications of diabetes, susceptibility to, 6, is related to type 1 diabetes mellitus and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 6 is SOD2 (Superoxide Dismutase 2). The drugs Pentoxifylline and Captopril have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612634 PS603933

Related Diseases for Microvascular Complications of Diabetes 6

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 553)
# Related Disease Score Top Affiliating Genes
1 type 1 diabetes mellitus 11.5
2 microvascular complications of diabetes 3 11.3
3 microvascular complications of diabetes 4 11.3
4 microvascular complications of diabetes 7 11.3
5 diabetic angiopathy 11.2
6 maturity-onset diabetes of the young 11.2
7 hyperglycemia 11.1
8 type 2 diabetes mellitus 11.1
9 renal fibrosis 11.1
10 oto-palatal-digital syndrome 11.0
11 diabetes mellitus 11.0
12 chronic kidney disease 11.0
13 glomerulonephritis 10.8
14 lipid metabolism disorder 10.8
15 nephrotic syndrome 10.7
16 hypertension, essential 10.7
17 rickets 10.7
18 vascular disease 10.7
19 ceroid lipofuscinosis, neuronal, 5 10.6
20 uremia 10.6
21 iga glomerulonephritis 10.6
22 iga nephropathy 1 10.6
23 membranous nephropathy 10.6
24 down syndrome 10.5
25 mckusick-kaufman syndrome 10.5
26 abdominal obesity-metabolic syndrome 1 10.5
27 hypercholesterolemia, familial, 1 10.5
28 cardiovascular system disease 10.5
29 neuropathy 10.5
30 kidney hypertrophy 10.5
31 peripheral vascular disease 10.5
32 glomerular disease 10.5
33 arteriosclerosis 10.5
34 lipoid nephrosis 10.5
35 leptin deficiency or dysfunction 10.5
36 focal segmental glomerulosclerosis 10.5
37 glucose intolerance 10.5
38 hypolipoproteinemia 10.5
39 deficiency anemia 10.5
40 pre-eclampsia 10.5
41 autonomic neuropathy 10.5
42 familial hyperlipidemia 10.5
43 diabetic neuropathy 10.5
44 cytokine deficiency 10.5
45 atherosclerosis susceptibility 10.4
46 hyperinsulinism 10.4
47 renal glucosuria 10.4
48 nephrosclerosis 10.4
49 tatton-brown-rahman syndrome 10.4
50 hyperuricemia 10.4

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 6:



Diseases related to Microvascular Complications of Diabetes 6

Symptoms & Phenotypes for Microvascular Complications of Diabetes 6

Clinical features from OMIM®:

612634 (Updated 08-Dec-2022)

Drugs & Therapeutics for Microvascular Complications of Diabetes 6

Drugs for Microvascular Complications of Diabetes 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Captopril Approved Phase 4 62571-86-2 44093
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Atenolol Approved Phase 4 29122-68-7 2249
9
Doxazosin Approved Phase 4 74191-85-8 3157
10
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
11
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
12
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
13
Simvastatin Approved Phase 4 79902-63-9 54454
14
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
15
Insulin glulisine Approved Phase 4 207748-29-6
16
Insulin glargine Approved Phase 4 160337-95-1 118984454
17
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
18
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
19
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
20
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
21
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
22
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
23
Carbamide peroxide Approved Phase 4 124-43-6
24
Candesartan cilexetil Approved Phase 4 145040-37-5
25
Allopurinol Approved Phase 4 315-30-0 2094 135401907
26
Nisoldipine Approved Phase 4 63675-72-9 4499
27
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
28
Probucol Approved, Investigational Phase 4 23288-49-5 4912
29
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
30
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
31
Atorvastatin Approved Phase 4 134523-00-5 60823
32
Indapamide Approved Phase 4 26807-65-8 3702
33
Insulin lispro Approved Phase 4 133107-64-9 16132438
34
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
35
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
36
Trandolapril Approved Phase 4 87679-37-6 5484727
37
Saxagliptin Approved Phase 4 361442-04-8 11243969
38
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
39
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
40
Ertugliflozin Approved, Investigational Phase 4 1210344-57-2 75075340 44814423
41
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
42
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
43
Losartan Approved Phase 4 114798-26-4 3961
44
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
45
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
46
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
47
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
48
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
49
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354

Interventional clinical trials:

(show top 50) (show all 279)
# Name Status NCT ID Phase Drugs
1 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Unknown status NCT04127084 Phase 4 SGLT2 Inhibition
2 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
3 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
4 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
5 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
6 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
7 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
8 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
9 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
10 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
11 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
12 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
13 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
14 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
15 A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus Completed NCT02276196 Phase 4 Lixisenatide;Insulin glulisine
16 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
17 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
18 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Completed NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
19 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
20 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil 32mg
21 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
22 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
23 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
24 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
25 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
26 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
27 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
28 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
29 Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen. Completed NCT00296296 Phase 4 Cyclosporin;Tacrolimus
30 Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea Completed NCT02816762 Phase 4 Pharmacological treatment
31 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH
32 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
33 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
34 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
35 Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes Completed NCT02914691 Phase 4 Dapagliflozine 10 mg once daily tablet treatment;Placebo identical once daily tablet treatment
36 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
37 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
38 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
39 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
40 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
41 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
42 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
43 A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy Completed NCT04521049 Phase 4 Saxagliptin 5mg
44 Phase 4, Randomized, Placebo-controlled, Cross-over Trial to Assess the Effect of 4-week Ertugliflozin (SGLT-2 Inhibitor) Therapy on Renal Oxygenation by BOLD-MRI and Renal Oxygen Consumption by PET Using ¹¹C-acetate in T2DM Without Kidney Disease and Healthy Controls. Recruiting NCT04027530 Phase 4 Ertugliflozin 15 mg
45 Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts. Recruiting NCT03502031 Phase 4 Renin-Angiotensin (RAAS) alone;Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
46 Study of Triple Blockade of the Renin Angiotensin Aldosterone System (RAAS) in Diabetic (Type 1&2) Proteinuric Patients With (ACE-, ARB, DRI) Terminated NCT00961207 Phase 4 Aliskiren
47 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
48 Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria Terminated NCT00171600 Phase 4 VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
49 A 24-Week Study to Assess Blood Pressure Independent Effects of Valsartan Treatment, Benazepril Treatment and Combination of Both Valsartan and Benazepril Treatment on Urinary Albumin Excretion Rate With Type II Diabetes Mellitus and Microalbuminuria Terminated NCT00171119 Phase 4 valsartan
50 The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy Terminated NCT00130312 Phase 4 Sulodexide;Placebo

Search NIH Clinical Center for Microvascular Complications of Diabetes 6

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 6

Genetic tests related to Microvascular Complications of Diabetes 6:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes, Susceptibility to, 6 28 SOD2

Anatomical Context for Microvascular Complications of Diabetes 6

Organs/tissues related to Microvascular Complications of Diabetes 6:

MalaCards : Kidney, Endothelial, Pancreas, Bone Marrow, Heart, Monocytes, Bone

Publications for Microvascular Complications of Diabetes 6

Articles related to Microvascular Complications of Diabetes 6:

(show top 50) (show all 20949)
# Title Authors PMID Year
1
A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. 62 57 5
17192491 2007
2
The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. 62 57 5
12624725 2003
3
Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. 57 5
16538174 2006
4
The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. 5
15591282 2004
5
Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. 5
10425186 1999
6
On signal sequence polymorphisms and diseases of distribution. 5
8633092 1996
7
Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice. 62
36375645 2023
8
Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy. 62
36280016 2023
9
Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence. 62
36341813 2023
10
Suppression of lncRNA Snhg1 inhibits high glucose-induced inflammation and proliferation in mouse mesangial cells. 62
36243327 2023
11
The changing trajectory of diabetic kidney disease. 62
36250469 2023
12
Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients. 62
36270460 2023
13
Ion channels and channelopathies in glomeruli. 62
36007181 2023
14
Modern indications for referral for kidney and pancreas transplantation. 62
36444661 2023
15
CircHOMER1 aggravates oxidative stress, inflammation and extracellular matrix deposition in high glucose-induced human mesangial cells. 62
36181383 2022
16
XIST silencing alleviated inflammation and mesangial cells proliferation in diabetic nephropathy by sponging miR-485. 62
32669002 2022
17
Haptoglobin Genotype Does Not Confer a Risk of Stroke in Type 1 Diabetes. 62
36409784 2022
18
Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. 62
36185030 2022
19
Differences in the Distribution of Ceramides and Sphingosine among Lipoprotein and Lipoprotein-Depleted Fractions in Patients with Type 2 Diabetes Mellitus. 62
35082227 2022
20
The roles of MTHFR (C677T, A1298C) and MGP (G-7A, T-138C) gene variations in development of diabetic nephropathy in patients with type 2 diabetes mellitus. 62
36404848 2022
21
Association between cause of kidney failure and fracture incidence in a national US dialysis population cohort study. 62
36381373 2022
22
Changes in the spectrum of kidney diseases: a survey of 2803 patients from 2010 to 2018 at a single center in southeastern China. 62
35656734 2022
23
Kidney biopsy during pregnancy: a difficult decision. A case series reporting on 20 patients from Mexico. 62
35994230 2022
24
Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention. 62
35535500 2022
25
MicroRNA-122-5p ameliorates tubular injury in diabetic nephropathy via FIH-1/HIF-1α pathway. 62
35166173 2022
26
Berberine protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition involving the inactivation of the NLRP3 inflammasome. 62
35618411 2022
27
Protective effect of salidroside on streptozotocin-induced diabetic nephropathy by inhibiting oxidative stress and inflammation in rats via the Akt/GSK-3β signalling pathway. 62
36086879 2022
28
Ranunculus ternatus Thunb extract attenuates renal fibrosis of diabetic nephropathy via inhibiting SMYD2. 62
35142600 2022
29
Peritoneal dialysis in the era of COVID-19: experience of a Tunisian center. 62
35913609 2022
30
Discovery of caffeoylisocitric acid as a Keap1-dependent Nrf2 activator and its effects in mesangial cells under high glucose. 62
34894983 2022
31
Addition of glomerular lesion severity improves the value of anemia status for the prediction of renal outcomes in Chinese patients with type 2 diabetes. 62
35188068 2022
32
High Glucose-Induced Human Kidney Cell Apoptosis and Inflammatory Injury Are Alleviated by Circ_0008529 Knockdown via Circ_0008529-Mediated miR-485-5p/WNT2B Signaling. 62
35913598 2022
33
Vitamin E functions by association with a novel binding site on the 67 kDa laminin receptor activating diacylglycerol kinase. 62
35977663 2022
34
Chronic kidney disease in public renal practices in Queensland, Australia, 2011-2018. 62
36161428 2022
35
Inhibition of the glycogen synthase kinase 3β-hypoxia-inducible factor 1α pathway alleviates NLRP3-mediated pyroptosis induced by high glucose in renal tubular epithelial cells. 62
36056793 2022
36
Redox phospholipidomics analysis reveals specific oxidized phospholipids and regions in the diabetic mouse kidney. 62
36334379 2022
37
Histopathology pattern and survival analysis of patients with kidney biopsy in the top end of Northern Australia from 2007 to 2020. 62
36456968 2022
38
Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. 62
36461735 2022
39
Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms. 62
36404838 2022
40
Effect of Costus pictus per se and in combination with Metformin and Enalapril in streptozotocin induced diabetic nephropathy in rats. 62
36404856 2022
41
Renoprotective activity of anethole- rich fraction from aromatic herbs on junk food induced diabetic nephropathy in rats. 62
36404830 2022
42
Emerging drugs for the treatment of diabetic nephropathy. 62
36472144 2022
43
Verteporfin inhibits the dedifferentiation of tubular epithelial cells via TGF-β1/Smad pathway but induces podocyte loss in diabetic nephropathy. 62
36375573 2022
44
Statement of Retraction: Diminution of microRNA-98 alleviates renal fibrosis in diabetic nephropathy by elevating Nedd4L and inactivating TGF-β/Smad2/3 pathway. 62
36346834 2022
45
Cynapanoside A exerts protective effects against obesity-induced diabetic nephropathy through ameliorating TRIM31-mediated inflammation, lipid synthesis and fibrosis. 62
36375322 2022
46
Expression of growth arrest specific 1 (Gas1) in the distal tubules and collecting ducts in normal kidney and in the early stages of diabetic nephropathy. 62
36272046 2022
47
Association of the expression pattern and functions of long non-coding RNA with the progression of diabetic nephropathy. 62
35718604 2022
48
NUP160 knockdown inhibits the progression of diabetic nephropathy in vitro and in vivo. 62
35785044 2022
49
Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. 62
36314849 2022
50
NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells. 62
36367498 2022

Variations for Microvascular Complications of Diabetes 6

ClinVar genetic disease variations for Microvascular Complications of Diabetes 6:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SOD2 NM_000636.4(SOD2):c.47T>C (p.Val16Ala) SNV Likely Risk Allele; Risk Factor
14751 rs4880 GRCh37: 6:160113872-160113872
GRCh38: 6:159692840-159692840

Expression for Microvascular Complications of Diabetes 6

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 6.

Pathways for Microvascular Complications of Diabetes 6

GO Terms for Microvascular Complications of Diabetes 6

Sources for Microvascular Complications of Diabetes 6

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....